TY - JOUR
T1 - Hypothesis-Driven, Structure-Based Design in Photopharmacology
T2 - The Case of eDHFR Inhibitors
AU - Kobauri, Piermichele
AU - Galenkamp, Nicole S
AU - Schulte, Albert M
AU - de Vries, Jisk
AU - Simeth, Nadja A
AU - Maglia, Giovanni
AU - Thallmair, Sebastian
AU - Kolarski, Dušan
AU - Szymanski, Wiktor
AU - Feringa, Ben L
PY - 2022/3/24
Y1 - 2022/3/24
N2 - Photopharmacology uses light to regulate the biological activity of drugs. This precise control is obtained through the incorporation of molecular photoswitches into bioactive molecules. A major challenge for photopharmacology is the rational design of photoswitchable drugs that show light-induced activation. Computer-aided drug design is an attractive approach toward more effective, targeted design. Herein, we critically evaluated different structure-based approaches for photopharmacology with Escherichia coli dihydrofolate reductase (eDHFR) as a case study. Through the iterative examination of our hypotheses, we progressively tuned the design of azobenzene-based, photoswitchable eDHFR inhibitors in five design-make-switch-test-analyze cycles. Targeting a hydrophobic subpocket of the enzyme and a specific salt bridge only with the thermally metastable cis-isomer emerged as the most promising design strategy. We identified three inhibitors that could be activated upon irradiation and reached potencies in the low-nanomolar range. Above all, this systematic study provided valuable insights for future endeavors toward rational photopharmacology.
AB - Photopharmacology uses light to regulate the biological activity of drugs. This precise control is obtained through the incorporation of molecular photoswitches into bioactive molecules. A major challenge for photopharmacology is the rational design of photoswitchable drugs that show light-induced activation. Computer-aided drug design is an attractive approach toward more effective, targeted design. Herein, we critically evaluated different structure-based approaches for photopharmacology with Escherichia coli dihydrofolate reductase (eDHFR) as a case study. Through the iterative examination of our hypotheses, we progressively tuned the design of azobenzene-based, photoswitchable eDHFR inhibitors in five design-make-switch-test-analyze cycles. Targeting a hydrophobic subpocket of the enzyme and a specific salt bridge only with the thermally metastable cis-isomer emerged as the most promising design strategy. We identified three inhibitors that could be activated upon irradiation and reached potencies in the low-nanomolar range. Above all, this systematic study provided valuable insights for future endeavors toward rational photopharmacology.
U2 - 10.1021/acs.jmedchem.1c01962
DO - 10.1021/acs.jmedchem.1c01962
M3 - Article
C2 - 35258959
SN - 0022-2623
VL - 65
SP - 4798
EP - 4817
JO - Journal of Medicinal Chemistry
JF - Journal of Medicinal Chemistry
IS - 6
M1 - 1c01962
ER -